<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Caspofungin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Caspofungin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Caspofungin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11313" href="/d/html/11313.html" rel="external">see "Caspofungin: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12914" href="/d/html/12914.html" rel="external">see "Caspofungin: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F146788"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cancidas</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866214"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Cancidas</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F146812"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antifungal Agent, Parenteral;</li>
<li>
                        Echinocandin</li></ul></div>
<div class="block doa drugH1Div" id="F146793"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="88c58fcb-77ef-4148-803b-f83c6e2aa28b">Aspergillosis, invasive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aspergillosis, invasive (including disseminated and extrapulmonary) (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for salvage therapy, typically as part of an appropriate combination regimen. Monotherapy is further reserved for patients who are intolerant of or refractory to azoles and polyenes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27365388','lexi-content-ref-15578352','lexi-content-ref-Patterson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27365388','lexi-content-ref-15578352','lexi-content-ref-Patterson.1'])">Ref</a></span>); for patients with severe or progressive infection, some experts use as initial therapy in combination with voriconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17103444','lexi-content-ref-15472810','lexi-content-ref-Patterson.1','lexi-content-ref-16477215']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17103444','lexi-content-ref-15472810','lexi-content-ref-Patterson.1','lexi-content-ref-16477215'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 70 mg on day 1, then 50 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27365388','lexi-content-ref-15578352']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27365388','lexi-content-ref-15578352'])">Ref</a></span>); if inadequate response, may increase dose to 70 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17103444','lexi-content-ref-Patterson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17103444','lexi-content-ref-Patterson.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Duration: When given as monotherapy, the minimum duration is 6 to 12 weeks depending on degree/duration of immunosuppression, disease site, and response to therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27365388'])">Ref</a></span>); immunosuppressed patients may require more prolonged treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30900296','lexi-content-ref-Patterson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30900296','lexi-content-ref-Patterson.1'])">Ref</a></span>). When given as part of a combination regimen, the optimal duration is uncertain. Some experts have given an echinocandin for ~2 weeks in combination with voriconazole before step-down to voriconazole monotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25599346']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25599346'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a474b86d-f618-403c-abc4-11a9a731c6ce">Candidiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Candidemia (neutropenic and nonneutropenic patients), including disseminated candidiasis:</i> IV:</b> 70 mg on day 1, then 50 mg once daily. Total duration (including oral step-down therapy) is ≥14 days after first negative blood culture and continues until signs/symptoms of candidemia and neutropenia, if present, have resolved; metastatic complications warrant a longer duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31155770','lexi-content-ref-26679628','lexi-content-ref-12490683']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31155770','lexi-content-ref-26679628','lexi-content-ref-12490683'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Cardiac device infection (including implantable cardiac defibrillator, pacemaker, ventricular assist device) (off-label use)</i></b>
<i>:</i>
<b>IV:</b> 150 mg once daily; step down to azole therapy in clinically stable patients with susceptible isolates and negative repeat cultures; total antifungal duration is ≥4 weeks after device removal for isolated generator pocket infection and ≥6 weeks after device removal for wire infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Chronic disseminated (hepatosplenic) (off-label use):</i></b>
<b>IV:</b> 70 mg on day 1, then 50 mg once daily for several weeks, followed by oral azole step-down therapy until lesion resolution and through periods of immunosuppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Empiric therapy, suspected invasive candidiasis (nonneutropenic ICU patients) (off-label use): </i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Antifungal therapy is not routinely warranted for initial management of nonneutropenic patients with sepsis. Consider use for critically ill patients with unexplained fever or unexplained hypotension despite broad-spectrum antimicrobial therapy and risk factors for invasive candidiasis (eg, indwelling venous catheter, hemodialysis, trauma or burns, recent surgery, parenteral nutrition) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628','lexi-content-ref-34599691','lexi-content-ref-Vazquez.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628','lexi-content-ref-34599691','lexi-content-ref-Vazquez.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 70 mg on day 1, then 50 mg once daily. For those who improve, continue empiric antifungal therapy for 2 weeks; consider discontinuing after 4 to 5 days in patients with no evidence of invasive candidiasis and no clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31155770','lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31155770','lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Endocarditis, native or prosthetic valve (off-label use):</i></b>
<b>IV:</b> 150 mg once daily(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17526917','lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17526917','lexi-content-ref-26679628'])">Ref</a></span>); step down to azole therapy in clinically stable patients with susceptible isolates and negative repeat cultures; total antifungal duration is ≥6 weeks after valve replacement surgery, with longer duration for perivalvular abscesses, other complications, or a nonsurgical approach (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Esophageal, refractory disease (alternative agent):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Reserve for fluconazole-refractory disease in patients who require IV therapy (eg, severe disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kauffman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kauffman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 70 mg on day 1, then 50 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31155770','lexi-content-ref-HHS.1','lexi-content-ref-26679628','lexi-content-ref-12361815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31155770','lexi-content-ref-HHS.1','lexi-content-ref-26679628','lexi-content-ref-12361815'])">Ref</a></span>); some experts give 50 mg once daily without a loading dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>), and other experts prefer 70 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kauffman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kauffman.1'])">Ref</a></span>). Transition to an oral antifungal once patient tolerates oral intake if susceptibility allows; total antifungal duration is 14 to 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1','lexi-content-ref-Kauffman.1','lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1','lexi-content-ref-Kauffman.1','lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Intra-abdominal infection (eg, peritonitis, abdominal abscess):</i> IV:</b> 70 mg on day 1, then 50 mg once daily. Total duration (including oral step-down therapy) is ≥14 days and continues until source control and clinical resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31155770','lexi-content-ref-26679628','lexi-content-ref-12490683','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31155770','lexi-content-ref-26679628','lexi-content-ref-12490683','lexi-content-ref-28085573'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Oropharyngeal, refractory disease (alternative therapy) (off-label use): </i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Reserve for fluconazole-refractory disease in patients who require IV therapy (eg, severe disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kauffman.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kauffman.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 70 mg on day 1, then 50 mg once daily. Transition to an oral antifungal once patient tolerates oral intake if susceptibility allows; total antifungal duration is 14 to 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628','lexi-content-ref-Kauffman.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628','lexi-content-ref-Kauffman.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Osteoarticular infection (osteomyelitis or septic arthritis) (off-label use):</i></b>
<b>IV:</b> 70 mg on day 1, then 50 to 70 mg once daily for ≥2 weeks; total duration of therapy (including oral step-down therapy) is 6 to 12 months for osteomyelitis and ≥6 weeks for septic arthritis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628','lexi-content-ref-Vazquez.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628','lexi-content-ref-Vazquez.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Thrombophlebitis, suppurative (off-label use):</i></b>
<b>IV:</b> 150 mg once daily; continue antifungal therapy until catheter removed and thrombus resolved, and for ≥2 weeks after candidemia (if present) has cleared (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4b4cc183-e762-44d3-9d4d-6ff926a219f3">Neutropenic fever, empiric antifungal therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutropenic fever, empiric antifungal therapy (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Recommended for patients with persistent or recurrent fever after ≥4 days of antimicrobial therapy when the duration of neutropenia is expected to exceed 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21258094','lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21258094','lexi-content-ref-27365388'])">Ref</a></span>). Some experts reserve for patients without suspicion of mold infection (eg, pulmonary nodules) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wingard.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wingard.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 70 mg on day 1, then 50 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15459300']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15459300'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c68abc8a-b79f-4368-a4bf-6161f16dfcf1">Prophylaxis against invasive fungal infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prophylaxis against invasive fungal infections (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Hematologic malignancy or hematopoietic cell transplant (alternative agent):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Some experts reserve for patients at low risk for mold infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30179565','lexi-content-ref-Wingard.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30179565','lexi-content-ref-Wingard.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 50 mg once daily. Duration is at least until resolution of neutropenia and varies based on degree and duration of immunosuppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30179565','lexi-content-ref-21258094','lexi-content-ref-27365388','lexi-content-ref-16377679']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30179565','lexi-content-ref-21258094','lexi-content-ref-27365388','lexi-content-ref-16377679'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Solid organ transplant (alternative agent):</i> IV:</b> 50 mg once daily; duration varies based on patient risk factors and transplant center protocol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31155770','lexi-content-ref-30900296','lexi-content-ref-Fishman.1','lexi-content-ref-26709146','lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31155770','lexi-content-ref-30900296','lexi-content-ref-Fishman.1','lexi-content-ref-26709146','lexi-content-ref-27365388'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990763"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Poorly dialyzed: No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.dor','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.dor','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed (highly protein bound): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.dor'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Poorly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28132647','lexi-content-ref-28035589','lexi-content-ref-23733471']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28132647','lexi-content-ref-28035589','lexi-content-ref-23733471'])">Ref</a></span>): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23733471']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23733471'])">Ref</a></span>). <b>Note:</b> Significant variability in caspofungin pharmacokinetics has been observed in critically ill patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17525052']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17525052'])">Ref</a></span>) and those on renal replacement therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28666752','lexi-content-ref-28035589']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28666752','lexi-content-ref-28035589'])">Ref</a></span>). Results of a Monte Carlo simulation suggest that instead of standard dosing (ie, 70 mg × 1 followed by 50 mg daily), a larger loading dose (ie, 100 mg) and maintenance dose of 50 mg once daily in patients &lt;80 kg or 70 mg once daily in patients &gt;80 kg increases the probability of achieving pharmacodynamic targets (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28035589']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28035589'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Unlikely to be significantly dialyzed: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.dor'])">Ref</a></span>). <b>Note:</b> Significant variability in caspofungin pharmacokinetics has been observed in critically ill patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17525052']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17525052'])">Ref</a></span>) and those on renal replacement therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28666752','lexi-content-ref-28035589']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28666752','lexi-content-ref-28035589'])">Ref</a></span>). Results of a Monte Carlo simulation suggest that instead of standard dosing (ie, 70 mg × 1 followed by 50 mg daily), a larger loading dose (ie, 100 mg) and maintenance dose of 50 mg once daily in patients &lt;80 kg or 70 mg once daily in patients &gt;80 kg increases the probability of achieving pharmacodynamic targets in patients on CRRT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28035589']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28035589'])">Ref</a></span>); these results are likely to be applicable to critically ill patients receiving PIRRT therapies as well (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.dor'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987792"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate impairment (Child-Pugh class B): 70 mg on day 1 (where recommended), followed by 35 mg once daily(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17660480','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17660480','lexi-content-ref-manu.1'])">Ref</a></span>); however, pharmacokinetic data suggest that this dose reduction may result in suboptimal drug exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29860319']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29860319'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling. Subsequent pharmacokinetic data suggest that degree of impairment (Child-Pugh class B or C) does not further decrease clearance of caspofungin and patients with severe impairment can be dosed the same as patients with moderate impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29860319']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29860319'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F146794"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F146803"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12914" href="/d/html/12914.html" rel="external">see "Caspofungin: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Caspofungin treatment duration should be based on patient status and clinical response.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7beae89c-e2c7-4a13-a271-1d760b3b7cc4">Aspergillosis, invasive; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aspergillosis, invasive; treatment: Note:</b> Guidelines recommend caspofungin for salvage therapy or where other antifungals are contraindicated; not recommended for routine use for primary treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27365388'])">Ref</a></span>). Infants ≥3 months, Children, and Adolescents &lt;18 years: IV: Initial 70 mg/m<sup>2</sup>/dose on day 1, then 50 mg/m<sup>2</sup>/dose once daily; may increase to 70 mg/m<sup>2</sup>/dose once daily if clinical response inadequate; maximum dose: 70 mg/dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="404c9b69-08aa-43dc-aeab-fa498e2c49a9">Fungal infections, empiric therapy in neutropenic patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fungal infections, empiric therapy in neutropenic patients</b>: Infants ≥3 months, Children, and Adolescents &lt;18 years: IV: Initial dose: 70 mg/m<sup>2</sup>/dose on day 1, then 50 mg/m<sup>2</sup>/dose once daily; may increase to 70 mg/m<sup>2</sup>/dose once daily if clinical response inadequate; maximum dose: 70 mg/dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="eb9e010d-bea3-4990-9fcf-1a19dbc8218f">Fungal infections, prophylaxis in patients with acute myeloid leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fungal infections, prophylaxis in patients with acute myeloid leukemia:</b> Limited data available: Infants ≥3 months, Children, and Adolescents: IV: Initial 70 mg/m<sup>2</sup>/dose on day 1 (maximum dose: 70 mg/dose), then 50 mg/m<sup>2</sup>/dose once daily (maximum dose: 50 mg/dose); begin therapy 24 to 72 hours following completion of each chemotherapy cycle and continue until ANC 100 to 500/µL following nadir or until next chemotherapy cycle, whichever occurs first (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31688884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31688884'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="70eedf49-2841-47e8-9487-706100719b57">Fungal infections, prophylaxis in allogeneic hematopoietic stem cell transplantation recipients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fungal infections, prophylaxis in allogeneic hematopoietic stem cell transplantation recipients:</b> Limited data available: Infants ≥8 months, Children, and Adolescents: IV: 50 mg/m<sup>2</sup>/dose once daily; maximum dose: 50 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22747637','lexi-content-ref-30314389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22747637','lexi-content-ref-30314389'])">Ref</a></span>); some studies used a loading dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28429246']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28429246'])">Ref</a></span>); guidelines recommend administering antifungal prophylaxis from the start of conditioning through engraftment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24424789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24424789'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d356b0af-fb9a-40c2-937a-2c5f2ea46abd">
<i>Candida</i> infections, treatment; independent of HIV status</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Candida </b></i>
<b>infections, treatment; independent of HIV status</b>:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &lt;3 months: Limited data available: IV: 25 mg/m<sup>2</sup>/dose once daily; dosing based on a pharmacokinetic study of 18 infants (PNA ≤12 weeks) that showed similar serum concentrations to standard adult doses (50 mg/day). Reported trough concentrations were slightly elevated and not correlated with increased adverse events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19075070']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19075070'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months, Children, and Adolescents &lt;18 years: IV: Initial 70 mg/m<sup>2</sup>/dose on day 1, then 50 mg/m<sup>2</sup>/dose once daily; may increase to 70 mg/m<sup>2</sup>/dose once daily if clinical response inadequate; maximum dose: 70 mg/dose. For esophageal disease, treat 14 to 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4','lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4','lexi-content-ref-26679628'])">Ref</a></span>). For candidemia, treat until 2 weeks after the last positive blood culture.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years: IV: Initial 70 mg on day 1, then 50 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>); for candidemia, treat until 2 weeks after the last positive blood culture and symptom resolution, and longer if neutropenia warrants; for esophageal disease, treat for 14 to 21 days. For esophageal disease, a higher rate of relapse has been reported with echinocandins than with fluconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.5'])">Ref</a></span>). Transition to fluconazole is recommended in clinically stable patients with fluconazole-susceptible isolates and negative repeat cultures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51083937"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants ≥3 months, Children, and Adolescents: No adjustment needed</p>
<p style="text-indent:-2em;margin-left:4em;">End-stage renal disease (ESRD) requiring dialysis: Poorly dialyzed; no supplemental dose or dosage adjustment necessary in patients on intermittent hemodialysis (IHD). No supplemental dose or dosage adjustment needed in peritoneal dialysis or continuous renal replacement therapy (eg, CVVHD) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1','lexi-content-ref-19397464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1','lexi-content-ref-19397464'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51083938"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); based on experience in adult patients, dosage reduction may be necessary; use with caution.</p></div>
<div class="block adr drugH1Div" id="F146762"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (adults: 3% to 20%; infants, children, and adolescents: 9%), peripheral edema (adults: 6% to 11%), tachycardia (7% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Chills (adults: 9% to 23%; infants, children, and adolescents: 13%), headache (9% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (4% to 23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (adults: 6% to 27%; infants, children, and adolescents: 7%), vomiting (6% to 17%), nausea (adults: 5% to 15%; infants, children, and adolescents: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hemoglobin (adults: 18% to 21%), decreased hematocrit (adults: 13% to 18%), decreased white blood cell count (adults: 12%), anemia (adults: 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase (adults: 9% to 22%), increased serum ALT (adults: 4% to 18%; infants, children, and adolescents: 5%), increased serum AST (adults: 6% to 16%; infants, children, and adolescents: 2%), increased serum bilirubin (adults: 5% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Localized phlebitis (adults: 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (adults: 3% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Respiratory failure (adults: 2% to 20%), cough (adults: 6% to 11%), pneumonia (adults: 4% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Infusion related reaction (20% to 35%), fever (6% to 30%), septic shock (adults: 11% to 14%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (5% to 9%), atrial fibrillation (&lt;5%), bradycardia (&lt;5%), cardiac arrhythmia (&lt;5%), edema (&lt;5%), flushing (&lt;5%), myocardial infarction (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Anxiety (&lt;5%), confusion (&lt;5%), depression (&lt;5%), dizziness (&lt;5%), drowsiness (&lt;5%), fatigue (&lt;5%), insomnia (&lt;5%), seizure (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema (5% to 9%), pruritus (infants, children, and adolescents: 6%), skin lesion (&lt;5%), urticaria (&lt;5%), decubitus ulcer (adults: 3% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypomagnesemia (adults: 7%), hyperglycemia (adults: 6%), hypokalemia (5% to 6%), hypercalcemia (&lt;5%), hypervolemia (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (4% to 9%), mucosal inflammation (4% to 6%), abdominal distention (&lt;5%), anorexia (&lt;5%), constipation (&lt;5%), decreased appetite (&lt;5%), dyspepsia (&lt;5%), upper abdominal pain (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (&lt;5%), nephrotoxicity (adults: 3%; serum creatinine ≥2 x baseline value or ≥1 mg/dL in patients with serum creatinine above ULN range)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Blood coagulation disorder (&lt;5%), febrile neutropenia (&lt;5%), neutropenia (&lt;5%), petechia (&lt;5%), thrombocytopenia (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Decreased serum albumin (adults: 7%), hepatic failure (&lt;5%), hepatomegaly (&lt;5%), hepatotoxicity (&lt;5%), hyperbilirubinemia (&lt;5%), jaundice (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis (adults: 5% to 7%), bacteremia (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Catheter infection (infants, children, and adolescents: 9%), infusion site reaction (&lt;5%; pain/pruritus/swelling)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (&lt;5%), back pain (&lt;5%), limb pain (&lt;5%), tremor (&lt;5%), weakness (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Hematuria (adults: 10%), increased blood urea nitrogen (adults: 4% to 9%), renal failure (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (adults: 9%), pleural effusion (adults: 9%), respiratory distress (adults: ≤8%), rales (adults: 7%), epistaxis (&lt;5%), hypoxia (&lt;5%), tachypnea (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, erythema multiforme, exfoliation of skin, hepatic necrosis, hepatitis, histamine release (including facial swelling, bronchospasm, sensation of warmth), increased gamma-glutamyl transferase, pancreatitis, renal insufficiency, Stevens-Johnson syndrome, swelling, toxic epidermal necrolysis</p></div>
<div class="block coi drugH1Div" id="F146775"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to caspofungin or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F146760"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Increased transaminases and rare cases of clinically significant hepatic dysfunction (including failure and hepatitis) have been reported in pediatric and adult patients. Monitor liver function tests during therapy; if tests become abnormal or worsen, consider discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Anaphylaxis, other hypersensitivity reactions, histamine-related reactions (eg, angioedema, facial swelling, bronchospasm, rash, sensation of warmth), and cases of Stevens-Johnson syndrome and toxic epidermal necrolysis (some fatal) have been reported. Discontinue if a hypersensitivity reaction occurs. Administer supportive treatment if needed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment. Dosage reduction may be necessary in adults with moderate impairment (Child-Pugh class B); safety and efficacy have not been established in children with any degree of hepatic impairment and adults with severe impairment (Child-Pugh class C).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Obesity: Data with another echinocandin suggest that clearance increases as a function of weight; higher doses may be necessary in patients with obesity (Hall 2011).</p></div>
<div class="block foc drugH1Div" id="F146769"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as acetate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cancidas: 50 mg (1 ea); 70 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg (1 ea); 70 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F146756"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323044"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Cancidas Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $405.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">70 mg (per each): $421.06</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Caspofungin Acetate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $82.80 - $404.40</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">70 mg (per each): $94.80 - $420.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866215"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cancidas: 50 mg (10.5 mL); 70 mg (10.5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg (1 ea); 70 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F146772"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Infuse slowly, over ~1 hour. Do not administer by IV bolus.</p></div>
<div class="block admp drugH1Div" id="F52612372"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV: Administer by slow IV infusion over 1 hour (manufacturer); higher doses (eg, 150 mg) have been infused over ~2 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19419331']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19419331'])">Ref</a></span>). Monitor during infusion; isolated cases of possible histamine-related reactions have occurred during clinical trials (rash, flushing, pruritus, facial edema).</p></div>
<div class="block use drugH1Div" id="F146770"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Aspergillosis, invasive:</b> Treatment of invasive aspergillosis in patients ≥3 months of age who are refractory to or intolerant of other therapies (eg, amphotericin B, lipid formulations of amphotericin B, itraconazole).</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Has not been studied as initial therapy for invasive aspergillosis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidemia and other <i>Candida </i> infections: </b>Treatment of candidemia and the following <i>Candida</i> infections in patients ≥3 months of age: Intra-abdominal abscesses, peritonitis, and pleural space infections.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Has not been studied in endocarditis, osteomyelitis, and meningitis due to <i>Candida</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis, esophageal:</b> Treatment of esophageal candidiasis in patients ≥3 months of age.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Not approved for the treatment of oropharyngeal candidiasis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutropenic fever, empiric antifungal therapy:</b> Empiric therapy for presumed fungal infections in febrile, neutropenic patients ≥3 months of age.</p></div>
<div class="block off-label drugH1Div" id="F25725033"><span class="drugH1">Use: Off-Label: Adult</span><p>Candidiasis, cardiac device infection (including implantable cardiac defibrillator, pacemaker, ventricular assist device); Candidiasis, chronic disseminated (hepatosplenic); Candidiasis, empiric therapy, suspected invasive candidiasis (nonneutropenic ICU patients); Candidiasis, endocarditis, native or prosthetic valve; Candidiasis, oropharyngeal, refractory disease; Candidiasis, osteoarticular infections (osteomyelitis or septic arthritis); Candidiasis, thrombophlebitis, suppurative; Prophylaxis against invasive fungal infections</p></div>
<div class="block cyt drugH1Div" id="F13298979"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F146764"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): May enhance the adverse/toxic effect of Caspofungin. CycloSPORINE (Systemic) may increase the serum concentration of Caspofungin. Caspofungin may increase the serum concentration of CycloSPORINE (Systemic). Management: Weigh potential benefits of caspofungin against a possible elevated risk of hepatotoxicity. Monitor liver function and re-evaluate treatment in patients with abnormal values. Mild transaminase elevations may occur relatively commonly.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inducers of Drug Clearance: May decrease the serum concentration of Caspofungin. Management: Consider using an increased caspofungin dose of 70 mg daily in adults (or 70 mg/m<sup>2</sup>, up to a maximum of 70 mg, daily in pediatric patients) when coadministered with known inducers of drug clearance.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Caspofungin. Management: Caspofungin prescribing information recommends using a dose of 70 mg daily in adults (or 70 mg/m<sup>2</sup>, up to a maximum of 70 mg, daily in pediatric patients) who are also receiving rifampin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saccharomyces boulardii: Antifungal Agents (Systemic and Oral [Non-Absorbable]) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F146777"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on animal data, in utero exposure to caspofungin may cause fetal harm.</p>
<p style="text-indent:0em;margin-top:2em;">When treatment of invasive <i>Aspergillus</i> or <i>Candida</i> infections is needed during pregnancy, other agents are preferred (HHS [OI adult 2020]; IDSA [Pappas 2016]).</p></div>
<div class="block brc drugH1Div" id="F16431935"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if caspofungin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F6273295"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Liver function; anaphylaxis, skin rash, or histamine-related reactions (eg, facial swelling, bronchospasm, sensation of warmth)</p></div>
<div class="block pha drugH1Div" id="F146759"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits synthesis of β(1,3)-D-glucan, an essential component of the cell wall of susceptible fungi. Highest activity is in regions of active cell growth. Mammalian cells do not require β(1,3)-D-glucan, limiting potential toxicity.</p></div>
<div class="block phk drugH1Div" id="F146774"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: CSF concentrations: Nondetectable [&lt;10 ng/mL (n=1)] (Sáez-Llorens 2009) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: ~97% to albumin </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Slowly, via hydrolysis and <i>N</i>-acetylation as well as by spontaneous degradation, with subsequent metabolism to component amino acids. Overall metabolism is extensive. </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Beta (distribution): 9 to 11 hours (~8 hours in children &lt;12 years); Terminal: 40 to 50 hours; beta phase half-life is 32% to 43% lower in pediatric patients than in adult patients </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (41%; primarily as metabolites, ~1% of total dose as unchanged drug); feces (35%; primarily as metabolites)</p></div>
<div class="block phksp drugH1Div" id="F51192706"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: AUC is increased 30% to 49% in patients with CrCl ≤49 mL/minute after administration of a single 70 mg dose. No effect on caspofungin concentrations was seen in patients with mild to end-stage renal impairment after administration of multiple daily doses.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: AUC is increased by ~55% in patients with mild hepatic impairment (Child-Pugh class A) and by 76% in patients with moderate hepatic impairment (Child-Pugh class B).</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: AUC is increased by ~28%.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: AUC in women was ~22% higher than in men after repeat dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">Obesity: Data with another echinocandin suggest that clearance increases as a function of weight (Hall 2011). From a small study of patients receiving caspofungin in the surgical ICU, body weight &gt;75 kg was an independent predictor for a lower 24-hour trough concentration (Nguyen 2007).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F146778"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Cancidas</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Caspofungina sandoz</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Caspofungin hikma | Caspofungin mylan | Caspofungin ratiopharm | Caspofungin stada</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Caspofungin an | Caspofungin myx</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Caspofungin sandoz | Caspofungin teva | Caspofungine mylan | Caspofungine noridem</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Cancidas</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Acetato de caspofungina | Berk | Cancidas</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Caspofungin mepha | Caspofungin mylan | Caspofungin sandoz</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Casfucid | Caspodyan | Caspofungina | Caspovitae | Sanicid | Suvepur</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Cancidas</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cafugin | Cancidas | Capsin | Caspofungina | Caspofungina acetato | Caspongyn | Caspovitae | Caxofu | Estasin | Kafum | Suvepur</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Caspofungin teva</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Caspofungin | Caspofungin amneal | Caspofungin beta | Caspofungin demo | Caspofungin hikma | Caspofungin inresa | Caspofungin lorien | Caspofungin mylan | Caspofungin Pharmore | Caspofungin ratiopharm | Caspofungin sandoz | Caspofungin stada | Caspofungin sun | Caspofungin tillomed | Caspofungin zentiva</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Cancidas</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Acetato de caspofungina | Cancidas | Caspof | Caspofungina | Caspofunzel | Caspovitae | Caxofu | Fungicas</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Caspofungin | Caspofungin sandoz | Dalvocans</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cancidas</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Caspofungina aristo | Caspofungina dr. reddy's | Caspofungina genfarma | Caspofungina Lorien | Caspofungina mylan | Caspofungina normon | Caspofungina sandoz | Caspofungina stada | Caspofungina sun | Caspofungina teva | Caspofungina tevagen</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Cancidas</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Caspofungin lorien | Caspofungin mylan | Caspofungin orion | Caspofungin stada</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Caspofungine Accord | Caspofungine altan | Caspofungine dr.reddy's | Caspofungine eg | Caspofungine fresenius kabi | Caspofungine mylan | Caspofungine Ohre pharma | Caspofungine sun | Caspofungine teva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Caspofungin | Caspofungin Dr. Reddy's</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Caspofungin accord | Caspofungin/demo | Caspofungin/teva | Fungizor</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Cancidas</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Cancidas</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Caspofungin onkogen | Caspofungin ratiopharm | Dalvocans</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Cancidas</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Caspofungin accord | Caspofungin Clonmel | Caspofungin Rowex</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Auxicasp | Bdcaspo | Cagin | Cancidas | Canducid | Capofin | Casfung | Casfungen | Casocan | Caspogard | Caspogin | Casponex | Casporan | Caspotaz | Casviogin | Savacap | Wofungin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Caspofungin | Caspofungin Dr. Reddy's | Caspofungin eg | Caspofungin hikma | Caspofungin Laboratorios Lorien | Caspofungin medac | Caspofungin mylan | Caspofungin sandoz | Caspofungin sun</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Cancidas</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Cancidas</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Casdin | Casfung | Caspogin | Kasiniv | Spogin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Penmix caspofungin acetate</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Cancidas</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Cancidas</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Dalvocans</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Caspofungin | Caspofungina | Fhanigun | Fiorella | Fuzitran | Karpilmex | Monmix | Suvepur | Tyspercan</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Cancidas</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Cancidas</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Caspofungine | Caspofungine Accord | Caspofungine cf | Caspofungine mylan | Caspofungine teva</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Caspofungin | Caspofungin lorien | Caspofungin mylan</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Caspofungin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Caspovitae</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Cancidas</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Caspofungin adamed | Caspofungin Fresenius Kabi | Caspofungin mylan | Caspofungin ranbax | Caspofungin Solinea | Caspofungin stada | Caspofungin zentiva | Dalvocans</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cancidas</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Caspofungin generis | Caspofungina farmoz | Caspofungina hikma | Caspofungina mylan | Caspofungina teva</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Bdcaspo</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Cancidas</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Caspofungina mylan | Caspofungina sandoz | Caspofungina stada | Caspofungina terapia | Caspofungina zentiva | Dalvocans</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Cansidas | Caspofungin | Caspofungin nativ | Maxcand</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Afundas l | Canvas | Caspofungin | Fungiska</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Caspofungin mylan | Caspofungin orion | Caspofungin sandoz | Caspofungin stada | Caspofungin teva | Kaspofungin lorien</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Cancidas</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Caspofungin teva | Kaspofungin stada</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Caspofungin mylan | Caspofungin sandoz | Caspofungin teva</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Cancidas</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cancidas</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Afundas l | Cancas | Cancidas | Casfugin | Caspobiem | Caspopol | Fungidas</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cancidas</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Cancidas</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Cancidas | Casfucid</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cancidas</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Casfolred | Caspofungin | Msd caspofungin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-28132647">
<a name="28132647"></a>Aguilar G, Ferriols R, Lozano A, et al. Optimal doses of caspofungin during continuous venovenous hemodiafiltration in critically ill patients. <i>Crit Care</i>. 2017;21(1):17. doi:10.1186/s13054-016-1594-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/28132647/pubmed" id="28132647" target="_blank">28132647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children.</i> 5th ed. Philadelphia, PA: American College of Physicians; 2007:61, 153.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31155770">
<a name="31155770"></a>Aslam S, Rotstein C; AST Infectious Disease Community of Practice. Candida infections in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13623. doi:10.1111/ctr.13623<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/31155770/pubmed" id="31155770" target="_blank">31155770</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19419331">
<a name="19419331"></a>Betts RF, Nucci M, Talwar D, et al, “A Multicenter, Double-Blind Trial of a High-Dose Caspofungin Treatment Regimen Versus a Standard Caspofungin Treatment Regimen for Adult Patients With Invasive Candidiasis,” <i>Clin Infect Dis</i>, 2009, 48(12):1676-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/19419331/pubmed" id="19419331" target="_blank">19419331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS and Nelson JD, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 25th ed. Itasca, IL: American Academy of Pediatrics; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cancidas.1">
<a name="Cancidas.1"></a>Cancidas (caspofungin) [prescribing information]. Rahway, NJ: Merck Sharp &amp; Dohme LLC; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>Candidiasis (Mucocutaneous). In: US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf</a>. Accessed June 16, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17526917">
<a name="17526917"></a>Cornely OA, Lasso M, Betts R, et al. Caspofungin for the treatment of less common forms of invasive candidiasis. <i>J Antimicrob Chemother.</i> 2007;60(2):363-369. doi:10.1093/jac/dkm169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/17526917/pubmed" id="17526917" target="_blank">17526917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22747637">
<a name="22747637"></a>Döring M, Hartmann U, Erbacher A, Lang P, Handgretinger R, Müller I. Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis. <i>BMC Infect Dis</i>. 2012;12:151.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/22747637/pubmed" id="22747637" target="_blank">22747637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34599691">
<a name="34599691"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021.<i> Intensive Care Med.</i> 2021;47(11):1181-1247. doi:10.1007/s00134-021-06506-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/34599691/pubmed" id="34599691" target="_blank">34599691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-expert.dor">
<a name="expert.dor"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31688884">
<a name="31688884"></a>Fisher BT, Zaoutis T, Dvorak CC, et al. Effect of caspofungin vs fluconazole prophylaxis on invasive fungal disease among children and young adults with acute myeloid leukemia: a randomized clinical trial. <i>JAMA</i>. 2019;322(17):1673-1681.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/31688884/pubmed" id="31688884" target="_blank">31688884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fishman.1">
<a name="Fishman.1"></a>Fishman JA, Alexander BD. Prophylaxis of infections in solid organ transplantation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26709146">
<a name="26709146"></a>Fortún J, Muriel A, Martín-Dávila P, et al; Grupo de Estudio de Infección en Pacientes Trasplantados-Grupo de Estudio de Micología Médica (Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica), and Red Española de Investigación en Patología Infecciosa. Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: a propensity score analysis. <i>Liver Transpl</i>. 2016;22(4):427-435. doi:10.1002/lt.24391<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/26709146/pubmed" id="26709146" target="_blank">26709146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21258094">
<a name="21258094"></a>Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2011;52(4):e56-e93. doi:10.1093/cid/cir073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/21258094/pubmed" id="21258094" target="_blank">21258094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22086858">
<a name="22086858"></a>Gould FK, Denning DW, Elliott TS, et al, “Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,” <i>J Antimicrob Chemother</i>, 2012, 67(2):269-89.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/22086858/pubmed" id="22086858" target="_blank">22086858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29860319">
<a name="29860319"></a>Gustot T, Ter Heine R, Brauns E, Cotton F, Jacobs F, Brüggemann RJ. Caspofungin dosage adjustments are not required for patients with Child-Pugh B or C cirrhosis. <i>J Antimicrob Chemother</i>. 2018;73(9):2493-2496. doi:10.1093/jac/dky189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/29860319/pubmed" id="29860319" target="_blank">29860319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21876061">
<a name="21876061"></a>Hall RG, Swancutt MA, Gumbo T. Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people. <i>Antimicrob Agents Chemother.</i> 2011;55(11):5107-5112. doi:10.1128/AAC.05193-11<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/21876061/pubmed" id="21876061" target="_blank">21876061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19397464">
<a name="19397464"></a>Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy</i>. 2009;29(5):562-577.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/19397464/pubmed" id="19397464" target="_blank">19397464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30900296">
<a name="30900296"></a>Husain S, Camargo JF. Invasive aspergillosis in solid-organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13544. doi:10.1111/ctr.13544<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/30900296/pubmed" id="30900296" target="_blank">30900296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30314389">
<a name="30314389"></a>Iosifidis E, Papachristou S, Roilides E. Advances in the treatment of mycoses in pediatric patients. <i>J Fungi (Basel)</i>. 2018;4(4):115.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/30314389/pubmed" id="30314389" target="_blank">30314389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24534016">
<a name="24534016"></a>Jeon GW, Sin JB. Successful caspofungin treatment of persistent candidemia in extreme prematurity at 23 and 24 weeks' gestation. <i>J Formos Med Assoc</i>. 2014;113(3):191-194.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/24534016/pubmed" id="24534016" target="_blank">24534016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kauffman.1">
<a name="Kauffman.1"></a>Kauffman CA. Esophageal candidiasis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed March 14, 2022c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kauffman.2">
<a name="Kauffman.2"></a>Kauffman CA. Oropharyngeal candidiasis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed June 17, 2021d.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28459614">
<a name="28459614"></a>Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. <i>J Clin Oncol</i>. 2017;35(18):2082-2094.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/28459614/pubmed" id="28459614" target="_blank">28459614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17103444">
<a name="17103444"></a>Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. <i>Cancer.</i> 2006;107(12):2888-2897.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/17103444/pubmed" id="17103444" target="_blank">17103444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15578352">
<a name="15578352"></a>Maertens J, Raad I, Petrikkos G, et al; Caspofungin Salvage Aspergillosis Study Group. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. <i>Clin Infect Dis</i>. 2004;39(11):1563-1571. doi:10.1086/423381<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/15578352/pubmed" id="15578352" target="_blank">15578352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15472810">
<a name="15472810"></a>Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. <i>Clin Infect Dis</i>. 2004;39(6):797-802. doi:10.1086/423380<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/15472810/pubmed" id="15472810" target="_blank">15472810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25599346">
<a name="25599346"></a>Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. <i>Ann Intern Med</i>. 2015;162(2):81-89. doi:10.7326/M13-2508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/25599346/pubmed" id="25599346" target="_blank">25599346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16377679">
<a name="16377679"></a>Mattiuzzi GN, Alvarado G, Giles FJ, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. <i>Antimicrob Agents Chemother</i>. 2006;50(1):143-147. doi:10.1128/AAC.50.1.143-147.2006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/16377679/pubmed" id="16377679" target="_blank">16377679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28429246">
<a name="28429246"></a>Maximova N, Schillani G, Simeone R, Maestro A, Zanon D. Comparison of efficacy and safety of caspofungin versus micafungin in pediatric allogeneic stem cell transplant recipients: a retrospective analysis. <i>Adv Ther</i>. 2017;34(5):1184-1199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/28429246/pubmed" id="28429246" target="_blank">28429246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28085573">
<a name="28085573"></a>Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. <i>Surg Infect (Larchmt)</i>. 2017;18(1):1-76. doi:10.1089/sur.2016.261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/28085573/pubmed" id="28085573" target="_blank">28085573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17660480">
<a name="17660480"></a>Mistry GC, Migoya E, Deutsch PJ, et al. Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations. <i>J Clin Pharmacol</i>. 2007;47(8):951-961.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/17660480/pubmed" id="17660480" target="_blank">17660480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21355042">
<a name="21355042"></a>Mohamed WA, Ismail M. A randomized, double-blind, prospective study of caspofungin vs. amphotericin B for the treatment of invasive candidiasis in newborn infants. <i>J Trop Pediatr</i>. 2012;58(1):25-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/21355042/pubmed" id="21355042" target="_blank">21355042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12490683">
<a name="12490683"></a>Mora-Duarte J, Betts R, Rotstein C, et al; Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. <i>N Engl J Med</i>. 2002;347(25):2020-2029.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/12490683/pubmed" id="12490683" target="_blank">12490683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17525052">
<a name="17525052"></a>Nguyen TH, Hoppe-Tichy T, Geiss HK, et al. Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. <i>J Antimicrob Chemother</i>. 2007;60(1):100-106. doi:10.1093/jac/dkm125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/17525052/pubmed" id="17525052" target="_blank">17525052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26679628">
<a name="26679628"></a>Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;62(4):e1-e50. doi: 10.1093/cid/civ933<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/26679628/pubmed" id="26679628" target="_blank">26679628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Patterson.1">
<a name="Patterson.1"></a>Patterson TF. Treatment and prevention of invasive aspergillosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 5, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27365388">
<a name="27365388"></a>Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;63(4):e1-e60. doi:10.1093/cid/ciw326<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/27365388/pubmed" id="27365388" target="_blank">27365388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28666752">
<a name="28666752"></a>Pérez-Pitarch A, Ferriols-Lisart R, Aguilar G, Ezquer-Garín C, Belda FJ, Guglieri-López B. Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on continuous venovenous haemodiafiltration. <i>Int J Antimicrob Agents</i>. 2018;51(1):115-121. doi:10.1016/j.ijantimicag.2017.05.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/28666752/pubmed" id="28666752" target="_blank">28666752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28035589">
<a name="28035589"></a>Roger C, Wallis SC, Muller L, et al. Caspofungin population pharmacokinetics in critically ill patients undergoing continuous veno-venous haemofiltration or haemodiafiltration. <i>Clin Pharmacokinet</i>. 2017;56(9):1057-1068. doi:10.1007/s40262-016-0495-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/28035589/pubmed" id="28035589" target="_blank">28035589</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19075070">
<a name="19075070"></a>Sáez-Llorens X, Macias M, Maiya P, et al, "Pharmacokinetics and Safety of Caspofungin in Neonates and Infants Less Than 3 Months of Age," <i>Antimicrob Agents Chemother</i>, 2009, 53(3):869-75.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/19075070/pubmed" id="19075070" target="_blank">19075070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24424789">
<a name="24424789"></a>Science M, Robinson PD, MacDonald T, Rassekh SR, Dupuis LL, Sung L. Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. <i>Pediatr Blood Cancer</i>. 2014;61(3):393-400.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/24424789/pubmed" id="24424789" target="_blank">24424789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16477215">
<a name="16477215"></a>Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. <i>Transplantation</i>. 2006;81(3):320-326. doi:10.1097/01.tp.0000202421.94822.f7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/16477215/pubmed" id="16477215" target="_blank">16477215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20034345">
<a name="20034345"></a>Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2010;50(2):133-164. doi:10.1086/649554<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/20034345/pubmed" id="20034345" target="_blank">20034345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi:10.1093/cid/ciu296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11952021">
<a name="11952021"></a>Stone EA, Fung HB, and Kirschenbaum HL, “Caspofungin: An Echinocandin Antifungal Agent,” <i>Clin Ther</i>, 2002, 24(3):351-77.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/11952021/pubmed" id="11952021" target="_blank">11952021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30179565">
<a name="30179565"></a>Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. <i>J Clin Oncol</i>. 2018;36(30):3043-3054. doi:10.1200/JCO.18.00374<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/30179565/pubmed" id="30179565" target="_blank">30179565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.5">
<a name="HHS.5"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents With HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new</a>. Updated November 21, 2019. Accessed January 22, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents With HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new</a>. Accessed April 29, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.3">
<a name="HHS.3"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new</a>. Updated December 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.4">
<a name="HHS.4"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new</a>. Updated December 9, 2019. Accessed January 22, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vazquez.1">
<a name="Vazquez.1"></a>Vazquez, JA. Candida osteoarticular infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 10, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vazquez.2">
<a name="Vazquez.2"></a>Vazquez JA. Management of candidemia and invasive candidiasis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 27, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12361815">
<a name="12361815"></a>Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. <i>Am J Med</i>. 2002;113(4):294-299. doi:10.1016/s0002-9343(02)01191-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/12361815/pubmed" id="12361815" target="_blank">12361815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16251293">
<a name="16251293"></a>Walsh TJ, Adamson PC, Seibel NL, et al, "Pharmacokinetics, Safety, and Tolerability of Caspofungin in Children and Adolescents," <i>Antimicrob Agents Chemother</i>, 2005, 49(11):4536-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/16251293/pubmed" id="16251293" target="_blank">16251293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15459300">
<a name="15459300"></a>Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. <i>N Engl J Med</i>. 2004;351(14):1391-1402. doi:10.1056/NEJMoa040446<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/15459300/pubmed" id="15459300" target="_blank">15459300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23733471">
<a name="23733471"></a>Weiler S, Seger C, Pfisterer H, et al. Pharmacokinetics of caspofungin in critically ill patients on continuous renal replacement therapy. <i>Antimicrob Agents Chemother</i>. 2013;57(8):4053-4057. doi:10.1128/AAC.00335-13<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/caspofungin-drug-information/abstract-text/23733471/pubmed" id="23733471" target="_blank">23733471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wingard.1">
<a name="Wingard.1"></a>Wingard JR. Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 30, 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9175 Version 270.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
